Hussman Strategic Advisors Inc. Buys Shares of 42,000 Wave Life Sciences Ltd. (NASDAQ:WVE)

Hussman Strategic Advisors Inc. acquired a new position in Wave Life Sciences Ltd. (NASDAQ:WVE) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 42,000 shares of the company’s stock, valued at approximately $520,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after buying an additional 856 shares during the last quarter. Kraematon Investment Advisors Inc. boosted its holdings in shares of Wave Life Sciences by 24.3% in the fourth quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock worth $246,000 after buying an additional 3,885 shares during the last quarter. KBC Group NV purchased a new position in shares of Wave Life Sciences in the fourth quarter worth approximately $67,000. US Bancorp DE boosted its holdings in shares of Wave Life Sciences by 53.9% in the third quarter. US Bancorp DE now owns 18,043 shares of the company’s stock worth $148,000 after buying an additional 6,316 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of Wave Life Sciences by 6.8% in the fourth quarter. New York State Common Retirement Fund now owns 109,084 shares of the company’s stock worth $1,349,000 after buying an additional 6,900 shares during the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Insider Transactions at Wave Life Sciences

In related news, CEO Paul Bolno sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $15.00, for a total value of $750,000.00. Following the sale, the chief executive officer now owns 217,351 shares in the company, valued at approximately $3,260,265. The trade was a 18.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 29.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Mizuho lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Truist Financial lifted their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. B. Riley lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Wave Life Sciences in a report on Wednesday, November 13th. Finally, StockNews.com downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Wave Life Sciences presently has an average rating of “Moderate Buy” and an average price target of $22.22.

Wave Life Sciences Price Performance

WVE stock opened at $11.33 on Friday. Wave Life Sciences Ltd. has a one year low of $3.95 and a one year high of $16.74. The company’s fifty day moving average price is $12.09 and its 200-day moving average price is $10.84.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.